These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20102365)

  • 1. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy.
    Brochot A; Zamacona M; Stockis A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):256-62. PubMed ID: 20102365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivaracetam for the treatment of epilepsy.
    Schulze-Bonhage A
    Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.
    Russo E; Citraro R; Mula M
    Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
    Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature rats.
    Dupuis N; Matagne A; Staelens L; Dournaud P; Desnous B; Gressens P; Auvin S
    Epilepsia; 2015 May; 56(5):800-5. PubMed ID: 25818358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
    Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H
    Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats.
    Ge YX; Lin YY; Bi QQ; Chen YJ
    Curr Neurovasc Res; 2020; 17(4):354-360. PubMed ID: 32407277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.
    Schoemaker R; Wade JR; Stockis A
    J Clin Pharmacol; 2016 Dec; 56(12):1591-1602. PubMed ID: 27146213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA
    Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brivaracetam for the treatment of epilepsy in adults.
    Mula M
    Expert Rev Neurother; 2014 Apr; 14(4):361-5. PubMed ID: 24625006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations.
    de Biase S; Gigli GL; Valente M
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):853-863. PubMed ID: 32853036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures.
    Schoemaker R; Wade JR; D'Souza J; Stockis A
    Epilepsy Res; 2017 Nov; 137():95-100. PubMed ID: 28982069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brivaracetam for the treatment of epilepsy.
    Klein P; Tyrlikova I; Brazdil M; Rektor I
    Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.